GLOX THERAPEUTICS LIMITED
🌿Early-stageactive
SC760230 · ltd · incorporated 2023-02-27
Investment thesis
Growth-phase business — story-led; valuation sensitive to momentum.
Why interesting: Trading is scaling; acquirers paying for trajectory get disproportionate leverage.
Why risky: Price often leads fundamentals; dependency on founder often high.
Why now
Window steady · low confidence
Stable recent picture — watch for any upcoming trigger event.
What changed my view
Last 30 days
No material changes in the last 30 days.
Last 90 days
No snapshot from 90 days ago — start tracking from today.
Last 180 days
No snapshot from 180 days ago — start tracking from today.
🔒Estimated value
—
Upgrade to see
Turnover
—
not disclosed
Net worth
—
book net assets
Opportunity
72/100
Strong
What this business does
Primary activity: Research and experimental development on biotechnology
Sector: Professional, scientific & technical
ALSO REGISTERED FOR
- 72190Other research and experimental development on natural sciences and engineering
Investor take
PursueStrong opportunity: active trading company with strong profile and acceptable with review structure.
Opportunity 72/100 (strong), bankability 70/100. Share purchase looks the cleaner deal structure. Most likely exit: share sale to pe / searcher (65/100).
Data confidence
Overall: medium (57/100)Adequate coverage. AI outputs are reliable for the sections scored high; verify the rest in diligence.
Company profile
address, 2 SIC codes, incorporation date
100
Financials
No iXBRL financials extracted
0
Lenders & charges
Confirmed no charges registered
85
Directors & officers
7 officers (3 active, 7 linked, 6 with DOB)
87
Ownership & PSC
0 active PSC(s) of 3 total, 3 with control declared
90
Director network
4 connected companies via shared directors
57
Filing history
31 filings on record
85
Gazette notices
No matching gazette notices (standard for active companies)
60
Opportunity Score
72/100Strong
PassWatchWorth a lookStrongExceptional
Solid opportunity signal. Worth a dedicated memo and management meeting.
Business quality
60
Adequate — check latest filings for context.
Acquirability
70
Strong succession / seller-readiness signals.
Risk profile
77
Few red flags.
Signal strength
90
Good data coverage for analysis.
Recent activity
Last 30 days
0
filings
Last 90 days
0
filings
Last 180 days
1
filing
- • 1 confirmation-statement
Counts from Companies House filing history.
Corporate timeline (34 events)Click to expand
- 2025-11-06📄appoint-person-director-company-with-name-dateofficers · AP01
- 2025-11-06📄termination-director-company-with-name-termination-dateofficers · TM01
- 2025-11-06📄termination-director-company-with-name-termination-dateofficers · TM01
- 2025-09-26➖CLARK, James Scott, Dr resigneddirector
- 2025-09-12📄accounts-with-accounts-type-smallaccounts · AA
- 2025-08-12➕NICKLIN, Paul, Dr appointeddirector
- 2025-08-12➖CZELOTH, Niklas, Dr resigneddirector
- 2025-07-21📄capital-allotment-sharescapital · SH01
- 2025-07-18📄termination-secretary-company-with-name-termination-dateofficers · TM02
- 2025-05-14➖BARCLAY, Patricia Barbara Ann resignedsecretary
- 2025-02-06➕MURRAY, Michael Stephen, Dr appointeddirector
- 2025-02-06📄appoint-person-director-company-with-name-dateofficers · AP01
- 2024-11-20📄notification-of-a-person-with-significant-control-statementpersons-with-significant-control · PSC08
- 2024-09-17📍change-registered-office-address-company-with-date-old-address-new-addressaddress · AD01
- 2024-08-19➖ANDERSON, Melville resigneddirector
- 2024-08-19📄termination-director-company-with-name-termination-dateofficers · TM01
- 2024-08-08📄accounts-with-accounts-type-smallaccounts · AA
- 2024-02-20📄change-account-reference-date-company-previous-shortenedaccounts · AA01
- 2024-01-18📄appoint-person-director-company-with-name-dateofficers · AP01
- 2024-01-18📄appoint-person-director-company-with-name-dateofficers · AP01
- 2024-01-17📄capital-allotment-sharescapital · SH01
- 2024-01-17📄cessation-of-a-person-with-significant-controlpersons-with-significant-control · PSC07
- 2024-01-09📄resolutionresolution · RESOLUTIONS
- 2024-01-09📄memorandum-articlesincorporation · MA
- 2023-10-24➕WALKER, Daniel, Professor appointeddirector
- 2023-10-24➕CZELOTH, Niklas, Dr appointeddirector
- 2023-05-16📄resolutionresolution · RESOLUTIONS
- 2023-05-16📄memorandum-articlesincorporation · MA
- 2023-05-16📄resolutionresolution · RESOLUTIONS
- 2023-05-15📄cessation-of-a-person-with-significant-controlpersons-with-significant-control · PSC07
- 2023-02-27🏢Company incorporatedAs GLOX THERAPEUTICS LIMITED
- 2023-02-27➕BARCLAY, Patricia Barbara Ann appointedsecretary
- 2023-02-27➕ANDERSON, Melville appointeddirector
- 2023-02-27➕CLARK, James Scott, Dr appointeddirector
Owner dependency
58/100
Moderate — manageable with handoverSome founder dependency, but not acute. A structured handover period should cover most risk.
FACTORS
- +Senior director age: Director aged approximately 63 — approaching natural succession window.
Succession & seller-readiness
50/100
Moderate signalSome succession indicators present. Worth watching; approach if sector/strategy fits.
SIGNALS
- primaryFounder aged 63+: Senior director is approximately 63. Approaching typical UK retirement age — succession thinking likely.
Red flags
1 med ·2 director resignations in last 12 months
mediumMultiple recent departures can indicate governance disagreement, succession event, or preparation for sale/stress.
Evidence: CLARK, James Scott, Dr resigned 2025-09-26; CZELOTH, Niklas, Dr resigned 2025-08-12
🔒Co-director network graph
Radial SVG graph showing every company connected via shared directors, colour-coded by status.
Available from the Pro tier upwards.
See pricing →Similar companies
Active · Professional services · G postcode area| Company | Est. value | Turnover | Net worth | Staff | Age | Opp | Director |
|---|---|---|---|---|---|---|---|
| MOULSDALE INVESTMENTS LIMITED→ SC491741 · est 2014 | £117.51M £86.58M–£148.43M | — | — | 118100 | 11y | 83 | 72y |
| MCGHEE GROUP LIMITED→ SC362390 · est 2009 | £20.62M £15.19M–£26.04M | — | — | — | 16y | 87 | 67y |
| I3WORKS LTD→ SC477423 · est 2014 | £16.71M £12.31M–£21.11M | £38.15M | — | 14200 | 12y | 92 | 61y |
| 24/26 HOLDINGS LTD→ SC470528 · est 2014 | £4.81M £3.54M–£6.07M | — | — | 26 | 12y | 85 | 67y |
| INTERLOCK INVESTMENTS LIMITED→ SC057982 · est 1975 | £3.26M £2.40M–£4.11M | — | — | 20 | 51y | 85 | 72y |
| SKYVISION INTERNATIONAL LIMITED→ SC153156 · est 1994 | £837.2k £616.9k–£1.06M | £680.4k | — | 100 | 31y | 88 | 65y |
| ACCU-TECH SYSTEMS LIMITED→ SC223891 · est 2001 | £22.3k £16.4k–£28.2k | £413.2k | — | 300 | 24y | 85 | 58y |
| 'A' FLIGHT AVIATION LIMITED→ SC157855 · est 1995 | — | — | £6.9k | — | 31y | 83 | 72y |
| AKELA PLANT HIRE LTD→ SC313584 · est 2006 | — | — | £1.74M | — | 19y | 83 | 58y |
| ANDERSON KNIGHT LIMITED→ SC214850 · est 2001 | — | — | — | 2300 | 25y | 83 | 63y |
| ASSISTING SUCCESS LIMITED→ SC294900 · est 2005 | — | — | £29.2k | — | 20y | 83 | 62y |
| BIO-IMAGES DRUG DELIVERY LTD→ SC383233 · est 2010 | — | — | — | 0 | 15y | 83 | 82y |
Peers ranked by estimated value, then turnover, then opportunity score.See all →
🔒Tailored diligence questions
7 specific questions generated from this company's actual signals — liquidity, leverage, director age, charge count, red flags, age-of-company.
Available from the Pro tier upwards.
See pricing →🔒Advanced scoring suite
Exit-route ranking, improvement thesis, quiet-distress detector, covenant-pressure proxy, extraction monitor, approaching triggers, ownership drift, local cluster, value trap, debt capacity, archetype classification — 48+ scoring modules.
Available from the Pro tier upwards.
See pricing →Company details
Statusactive
Typeltd
Incorporated2023-02-27
Jurisdictionscotland
Primary SIC72110 — Research and experimental development on biotechnology
Registered office
John Arbuthnott Building Strathclyde University Of Pharmacy & Biomedical
161 Cathedral Street
Glasgow
G4 0RE
Scotland
Filing status
Accounts
Next due: 2026-09-30
Last made up to: 2024-12-31
Confirmation statement
Next due: 2027-03-12
Last: 2026-02-26
Officers (3 active · 4 resigned)
MURRAY, Michael Stephen, Dr→
Activedirector · ~63y · appointed 2025-02-06
View their other companies + combined net worth →
NICKLIN, Paul, Dr→
Activedirector · ~59y · appointed 2025-08-12
View their other companies + combined net worth →
WALKER, Daniel, Professor→
Activedirector · ~53y · appointed 2023-10-24
View their other companies + combined net worth →
BARCLAY, Patricia Barbara Ann→
Resignedsecretary · appointed 2023-02-27 · resigned 2025-05-14
ANDERSON, Melville→
Resigneddirector · ~61y · appointed 2023-02-27 · resigned 2024-08-19
CLARK, James Scott, Dr→
Resigneddirector · ~58y · appointed 2023-02-27 · resigned 2025-09-26
CZELOTH, Niklas, Dr→
Resigneddirector · ~50y · appointed 2023-10-24 · resigned 2025-08-12
Click a director name to see their full track record across all companies.
Recent filings (31 total)
confirmation-statement-with-updates
confirmation-statement · CS01
2026-03-26
appoint-person-director-company-with-name-date
officers · AP01
2025-11-06
termination-director-company-with-name-termination-date
officers · TM01
2025-11-06
termination-director-company-with-name-termination-date
officers · TM01
2025-11-06
accounts-with-accounts-type-small
accounts · AA
2025-09-12
capital-allotment-shares
capital · SH01
2025-07-21
termination-secretary-company-with-name-termination-date
officers · TM02
2025-07-18
confirmation-statement-with-no-updates
confirmation-statement · CS01
2025-03-26
appoint-person-director-company-with-name-date
officers · AP01
2025-02-06
notification-of-a-person-with-significant-control-statement
persons-with-significant-control · PSC08
2024-11-20
change-registered-office-address-company-with-date-old-address-new-address
address · AD01
2024-09-17
termination-director-company-with-name-termination-date
officers · TM01
2024-08-19
accounts-with-accounts-type-small
accounts · AA
2024-08-08
confirmation-statement-with-updates
confirmation-statement · CS01
2024-03-22
change-account-reference-date-company-previous-shortened
accounts · AA01
2024-02-20